Education
About Us
Working with TipRanks
Follow Us
Tscan Therapeutics, Inc. (TCRX)
:TCRX
TCRX Analyst Ratings
Moderate Buy
5 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TCRX Stock 12 Month Forecast
Average Price Target
$5.50
▲(444.55% Upside)
| Highest Price Target$7.00 | Average Price Target$5.50 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
$6
Buy
494.06%
Upside
Reiterated
12/09/25
BTIG
―
Hold
―
Reiterated
12/09/25
H.C. Wainwright
$7
Buy
593.07%
Upside
Reiterated
12/08/25
Promising Potential of TScan Therapeutics' TSC-101: Analyst Recommends Buy RatingValuation and Risks. Our price target of $7 is based on an equally weighted composite of: (a) $8.98/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $1.35 discounted back to and (b) an NPV of $5.5/ share (discount rate 12%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) regulatory risk; (2) commercial risks; (3) clinical development risks; (4) manufacturing risks; (5) financial risks; (6) liability risks; and (7) intellectual property risk.
Morgan Stanley
―
Hold
―
Reiterated
12/08/25
LifeSci Capital
$6
Buy
494.06%
Upside
Reiterated
11/12/25
TD Cowen
―
Buy
―
Reiterated
11/12/25
Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics1:27 PM TScan Therapeutics (NASDAQ: TCRX) Buy (1) ESG Target: NA 2-Year Relapse Data At ASH Report THE TD COWEN INSIGHT 2-year relapse data from the Phase I ALLOHA trial of TSC-101 in heme malignancies are expected by YE, where durability should improve upon the ~42% benchmark given the 18% relapse rate observed thus far. These data should de-risk the pivotal trial, which is now expected to initiate in Q2 following FDA feedback and an updated trial design. Solid tumors are halted to focus efforts on in-vivo TCR-T.
Barclays
$3
Buy
197.03%
Upside
Reiterated
11/04/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
$6
Buy
494.06%
Upside
Reiterated
12/09/25
BTIG
―
Hold
―
Reiterated
12/09/25
H.C. Wainwright
$7
Buy
593.07%
Upside
Reiterated
12/08/25
Promising Potential of TScan Therapeutics' TSC-101: Analyst Recommends Buy RatingValuation and Risks. Our price target of $7 is based on an equally weighted composite of: (a) $8.98/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $1.35 discounted back to and (b) an NPV of $5.5/ share (discount rate 12%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) regulatory risk; (2) commercial risks; (3) clinical development risks; (4) manufacturing risks; (5) financial risks; (6) liability risks; and (7) intellectual property risk.
Morgan Stanley
―
Hold
―
Reiterated
12/08/25
LifeSci Capital
$6
Buy
494.06%
Upside
Reiterated
11/12/25
TD Cowen
―
Buy
―
Reiterated
11/12/25
Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics1:27 PM TScan Therapeutics (NASDAQ: TCRX) Buy (1) ESG Target: NA 2-Year Relapse Data At ASH Report THE TD COWEN INSIGHT 2-year relapse data from the Phase I ALLOHA trial of TSC-101 in heme malignancies are expected by YE, where durability should improve upon the ~42% benchmark given the 18% relapse rate observed thus far. These data should de-risk the pivotal trial, which is now expected to initiate in Q2 following FDA feedback and an updated trial design. Solid tumors are halted to focus efforts on in-vivo TCR-T.
Barclays
$3
Buy
197.03%
Upside
Reiterated
11/04/25
Best Analysts Covering TScan Therapeutics
1 Month
xxx
Success Rate
6/18 ratings generated profit
Average Return
-2.04%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -2.04% per trade.
3 Months
xxx
Success Rate
5/13 ratings generated profit
Average Return
-11.16%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of -11.16% per trade.
1 Year
Success Rate
4/18 ratings generated profit
Average Return
-17.16%
reiterated a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -17.16% per trade.
2 Years
xxx
Success Rate
0/18 ratings generated profit
Average Return
-59.24%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -59.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TCRX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
6
6
8
9
Buy
1
1
1
1
1
Hold
11
9
11
11
13
Sell
0
0
0
2
2
Strong Sell
0
0
0
0
0
total
17
16
18
22
25
Each month's total comprises the sum of three months' worth of ratings.
TCRX Financial Forecast
TCRX Stock Forecast FAQ
What is TCRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Tscan Therapeutics, Inc.’s 12-month average price target is 5.50.
What is TCRX’s upside potential, based on the analysts’ average price target?
Tscan Therapeutics, Inc. has 444.55% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TCRX a Buy, Sell or Hold?
Tscan Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
What is Tscan Therapeutics, Inc.’s price target?
The average price target for Tscan Therapeutics, Inc. is 5.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $3.00. The average price target represents 444.55% Increase from the current price of $1.01.
The highest analyst price target is $7.00 ,the lowest forecast is $3.00. The average price target represents 444.55% Increase from the current price of $1.01.
What do analysts say about Tscan Therapeutics, Inc.?
Tscan Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of TCRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.